2025-10-05 - Analysis Report
Okay, here's an analysis of Recursion Pharmaceuticals (RXRX), incorporating all the provided data.  I'll present the key metrics, followed by analysis and a summary.

**Report on Recursion Pharmaceuticals Inc. (RXRX)**

**Company Overview:** Recursion Pharmaceuticals is a clinical-stage biotechnology company leveraging AI and machine learning to discover and develop novel therapeutics.

**1. Performance vs. S&P 500 (VOO)**

*   **RXRX Cumulative Return:** -12.36%
*   **VOO Cumulative Return:** 40.49%
*   **Spread:** -52.85%
*   **Relative Spread:** 8.1 (meaning RXRX's underperformance is in the lower range of its historical relative performance compared to the S&P 500).

**Alpha/Beta Analysis:**

| Year       | CAGR    | MDD  | Alpha | Beta  | Cap(B) |
| :----------- | :------ | :----- | :------ | :----- | :------ |
| 2021-2023  | 22.0%  | 81.0% | 26.0%  | -0.2  | 4.3    |
| 2022-2024  | 11.0%  | 81.0% | -10.0% | 0.1  | 3.0    |
| 2023-2025  | 30.0%  | 80.0% | -33.0% | 0.1  | 2.4    |

**Analysis:**

*   The significant negative spread indicates substantial underperformance compared to the S&P 500.
*   The relative spread of 8.1 suggests that while RXRX is underperforming, it's at the lower end of its historical underperformance range, implying some potential for improvement.
*   **Alpha/Beta Analysis**:
    *   The alpha values fluctuate significantly, showing inconsistent outperformance relative to the market. In recent period is significantly negative.
    *   The beta values are very low (close to zero), indicating that RXRX's price movements are not strongly correlated with the S&P 500. This suggests the stock is more influenced by company-specific factors than broader market trends.
    *   The high MDD (Maximum Drawdown) values indicate significant volatility and risk.

**2. Recent Stock Price Movement**

*   **Current Price:** $5.49
*   **Previous Close:** $5.52
*   **Change:** -0.54%
*   **5-Day Moving Average:** 5.164
*   **20-Day Moving Average:** 4.8857
*   **60-Day Moving Average:** 5.2507

**Analysis:**

*   The current price is slightly down from the previous close.
*   The 5-day moving average is above the 20-day and 60-day moving averages, suggesting a short-term upward trend.

**3. Market Risk Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (Medium to High Investment Recommended)
*   **RSI:** 70.11 (Overbought)
*   **PPO:** 1.93
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (195 shares - Very Safe - MRI:0.90) Monthly invest 1.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **20-Day Relative Spread Change:** +8.1 (Short-term Increase)
*   **Expected Return:** -49.2% (Long-term underperformance vs. S&P 500)

**Analysis:**

*   The MRI suggests a moderate to high investment recommendation, potentially due to the company's growth prospects despite the risks.
*   The RSI is above 70, indicating the stock is overbought and might be due for a correction.
*   The PPO is positive, suggesting an upward trend.
*   The Hybrid Signal suggests a full investment strategy, indicating confidence in the stock's potential.
*   A significant negative expected return signals the stock is expected to underperform the S&P 500 in the long term.
*   The price change is small (-0.54%), so no significant volatility issues should be noticed.

**4. Recent News & Analyst Opinions**

*   **Positive News:**
    *   RXRX Surges 8.2% (Zacks)
    *   Recursion After a 19% Rally Amid Renewed Interest in Biotech AI Initiatives (Simply Wall St.)
    *   Needham Reiterates a Buy (Insider Monkey)
*   **Cautious/Mixed News:**
    *   Jim Cramer: "I Need to See a Proof of Concept Here" (Insider Monkey)
    *   Where Will Recursion Be in 5 Years? (Motley Fool)
    *   The Biotech Stock That's Too Risky (Motley Fool)

**Analyst Opinions:**

*   **Consensus:** Neutral
*   **Mean Rating:** -
*   **Opinions:** 6
*   **Target Price:** $6.47 (Avg), $10.00 (High), $3.00 (Low)
*   **Recent Rating Changes:** No specific changes provided

**Analysis:**

*   Recent news is mixed, with some positive headlines about recent price surges and analyst reiterations of "Buy" ratings. However, there are also cautionary notes about the need for proof of concept and the stock's inherent risk.
*   Analyst opinions are somewhat neutral, reflected by the lack of a strong consensus rating. The target price range is wide, indicating significant uncertainty about the stock's future performance.

**5. Recent Earnings Analysis**

| Date       | EPS   | Revenue      |
| :----------- | :------ | :------------- |
| 2025-08-05 | -0.41 | $0.02B |
| 2025-05-05 | -0.5  | $0.01B |
| 2024-11-06 | -0.34 | $0.03B |
| 2024-08-08 | -0.4  | $0.01B |
| 2025-08-05 | -0.4  | $0.01B |

**Analysis:**

*   EPS is consistently negative, indicating that the company is not profitable.
*   Revenue fluctuates, but generally remains low.

**6. Financial Information**

Revenue and Profitability:

| Quarter    | Revenue    | Profit Margin |
| :--------- | :--------- | :-------------- |
| 2025-06-30 | \$0.02B   | -5.54%          |
| 2025-03-31 | \$0.01B   | -47.31%         |
| 2024-12-31 | \$0.00B   | -183.62%        |
| 2024-09-30 | \$0.03B   | 53.69%          |
| 2024-06-30 | \$0.01B   | 36.14%          |

Capital and Profitability:

| Quarter    | Equity    | ROE      |
| :--------- | :---------- | :------- |
| 2025-06-30 | \$0.92B   | -18.70% |
| 2025-03-31 | \$0.93B   | -21.68% |
| 2024-12-31 | \$1.03B   | -17.29% |
| 2024-09-30 | \$0.52B   | -18.27% |
| 2024-06-30 | \$0.58B   | -16.69% |

**Analysis:**

*   **Revenue and Profitability:** Revenue is inconsistent and relatively low. Profit margins are generally negative, indicating that the company is struggling to generate profits from its revenue. The large negative profit margin in 2024-12-31 indicates significant losses during that quarter.
*   **Capital and Profitability:** Equity values are relatively high, indicating a substantial asset base. However, the negative ROE values indicate that the company is not effectively utilizing its equity to generate profits. The significant jump in equity between 2024-09-30 and 2024-12-31 could be due to a capital raise or other financial event.

**7. Overall Summary**

Recursion Pharmaceuticals (RXRX) presents a mixed investment picture.

**Positive Aspects:**

*   **Innovative Approach:** The company's use of AI and machine learning in drug discovery is a potentially disruptive and valuable approach.
*   **Recent Price Momentum:** The recent price surge and "Buy" reiterations from some analysts indicate short-term positive momentum.
*   **Strong MRI:** The Market Risk Indicator suggests a moderate to high investment recommendation.
*   **Relatively High Equity:** The company has a significant asset base, as indicated by its high equity values.

**Negative Aspects:**

*   **Significant Underperformance:** RXRX has significantly underperformed the S&P 500.
*   **Unprofitability:** The company is currently unprofitable, with negative EPS and inconsistent revenue.
*   **High Risk:** The high MDD and negative expected return highlight the stock's inherent risk.
*   **Negative ROE:** The negative Return on Equity values indicate that the company is not effectively utilizing its equity to generate profits.
*   **Mixed Analyst Opinions:** Analyst opinions are mixed, with a wide target price range reflecting uncertainty.

**Conclusion:**

RXRX is a high-risk, high-reward investment. Its innovative approach and recent positive momentum are appealing, but the company's unprofitability, underperformance, and mixed analyst opinions should give investors pause. A careful assessment of risk tolerance and investment horizon is crucial before considering an investment in RXRX. Investors should closely monitor the company's progress in generating revenue and achieving profitability, as well as any developments in its drug discovery pipeline. Investors should also consider the high volatility (high MDD) before investing.
